Product hub: Targeted protein degradation – next-generation therapeutics
Posted: 27 September 2022 | BMG Labtech GmbH | No comments yet
Helen Harrison, Director of Screening at Amphista Therapeutics, discusses targeted protein degradation (TPD) and the discovery of drugs in this area.
TPD approaches can completely remove pathogenic proteins, rather than just inhibiting their function, providing potential for more potent or broader pharmacology, improved selectivity and better sustained in vivo effects. There has been an increasing focus on assays such as three-dimensional (3D) cell culture, complex co-cultures and patient-derived cells, which can more accurately predict how a molecule will behave in vivo. We have also seen a recent increase in the use of bioinformatics and artificial intelligence (AI) techniques to identify new targets and re-purpose current molecules.
Related content from this organisation
- Product hub: Targeted protein degradation – next-generation therapeutics
- ebook: Binding kinetics in drug discovery
- Application note: Competitive high-throughput analysis of kinase inhibitor binding kinetics
- Product hub: High-throughput screening of cyclic peptide libraries for developing drugs to challenging targets
- Application note: Screening for optimal association and dissociation rates of ligands using a live cell binding assay
Related topics
Cell Cultures, Cell-based assays, Drug Discovery, Protein, Proteomics, Screening, Target Molecule, Therapeutics
Related organisations
BMG Labtech GmbH
